Phase II study of Platinum-Based Doublet Chemotherapy plus Atezolizumab, in completely resected, p-stage II-IIIA NSCLC patients harboring EGFR mutation. (WJOG11719L Investigator-Initiated Clinical Trial)
Latest Information Update: 12 Aug 2022
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin (Primary) ; Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Dec 2021 Planned initiation date changed from 1 Aug 2019 to NULL.
- 19 Dec 2021 Status changed from not stated to recruiting.
- 19 Dec 2021 New trial record